Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208633 | 1.00 | GSK3A (0.33) | GSK3AGSK3BCYP1A2MGAMGAA | |
| SCHEMBL11167668 | 0.84 | GSK3A (0.34) | GSK3AGSK3BCYP1A2MGAMGAA | |
| SCHEMBL6924804 | 0.77 | GSK3A (0.41) | GSK3AGSK3BCYP1A2MGAMGAA | |
| SCHEMBL31598498 | 0.74 | GSK3A (0.35) | GSK3AGSK3BCYP1A2MGAMGAA | |
| SCHEMBL20495271 | 0.74 | GSK3A (0.35) | GSK3AGSK3BCYP1A2MGAMGAA | |
| SCHEMBL7398001 | 0.62 | CYP1A2 (0.48) | CYP1A2IDO1TSHRHSD17B10ALDH1A1 | |
| SCHEMBL9141430 | 0.61 | GSK3A (0.37) | GSK3AGSK3BCYP1A2MGAMGAA | |
| SCHEMBL736634 | 0.61 | GSK3A (0.40) | GSK3AGSK3BCYP1A2MGAMGAA | |
| SCHEMBL30565914 | 0.60 | ALDH1A1 (0.40) | GSK3AGSK3BCYP1A2MGAMGAA | |
| Ethoxycarbonyl Group SCHEMBL2078915 | 0.59 | GAA (0.44) | GSK3AGSK3BCYP1A2MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962919-B2 | Nitrogen-containing heterocyclic compounds, their production and use | TAKEDA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-08 | — | — | US | disclosed |
| EP-1042325-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20020103210-A1 | Nitrogen-containing heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2002-08-01 | — | — | US | disclosed |
| US-6413972-B1 | 5,8-DIHYDRO-3-METHYL-5-OXO-8-(1-OXO-1-PHENYL-2-PROPYL)-2 -PHENYLIMIDAZO(1,2-A)PYRIMIDINE-6-CARBOXYLIC ACID ETHYL ESTER; GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; LOW TOXICITY; ANTICARCINOGENIC AGENT; CONTRACEPTIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| US-6194419-B1 | THERAPY FOR SEXUAL DISORDERS; A 5-OXOIMIDAZOLO(1,2-A)PYRIMIDINE-6-CARBOXYLIC ESTER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-1042325-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033831-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103210-A1 | Nitrogen-containing heterocyclic compounds, their production and use | GNRHR, NR5A1, SHBG | GSK3A 4376/4885GSK3B 4276/4885CYP1A2 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.